Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
September 01, 2022 07:00 ET
|
Skye Bioscience, Inc.
San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
July 21, 2022 07:00 ET
|
Skye Bioscience, Inc.
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the...
Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
June 07, 2022 07:00 ET
|
Skye Bioscience, Inc.
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE...
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
April 28, 2022 07:00 ET
|
Skye Bioscience, Inc.
San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
February 01, 2022 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
August 10, 2021 08:30 ET
|
Skye Bioscience, Inc.
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical...
Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors
July 26, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
March 16, 2021 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...